目的 分析枞阳县接受高效抗反转录病毒治疗(HAART)的艾滋病病毒感染者和病人(HIV/AIDS)生存率及影响因素,为提高HAART工作质量提供参考依据。方法 采用回顾性队列研究方法,收集枞阳县2009—2019年接受HAART治疗HIV/AIDS患者的数据资料,采用寿命表计算生存率,Kaplan-Meier法、Cox回归模型分析其影响因素。结果 共纳入治疗对象185例,平均观察时间为(6.54±3.28)年,因艾滋病相关疾病死亡17例。治疗后1、3、5、10年的累计生存率分别为95.00%、93.00%、92.00%、89.00%,单因素分析结果显示,开始抗病毒治疗年龄小、基线CD4+T淋巴细胞计数高、已婚双阳家庭、文化程度高、无漏服药、家人支持而非歧视、经济条件好是HAART治疗HIV/AIDS患者生存时间的保护因素;多因素分析结果显示,开始抗病毒治疗年龄小、基线CD4+T淋巴细胞计数高、经济条件好的HAART治疗HIV/AIDS 患者死亡风险相对较低。结论 开始抗病毒治疗年龄、基线CD4+T淋巴细胞计数、经济条件是HAART治疗HIV/AIDS患者生存时间的影响因素。
Abstract
Objective To analyze the survival rate and influencing factors of HIV infected persons and patients (HIV/AIDS) receiving highly active antiretroviral therapy (HAART) in Zongyang County,and to provide reference for improving the quality of HAART work. Methods Retrospective cohort study was used to collect the data of HIV/AIDS patients who received HAART treatment in Zongyang County from 2009 to 2019.Life table was used to calculate the survival rate.Kaplan-Meier method and Cox regression model were used to analyze the influencing factors. Results Totally,185 HIV/AIDS patients were included in the treatment,with the average observation time (6.54±3.28) years.17 patients died of AIDS related diseases.The cumulative survival rates at 1 year,3 years,5 years,and 10 years after treatment were 95.00%,93.00%,92.00% and 89.00%,respectively.The univariate analysis results showed that young age at the beginning of antiviral treatment,high baseline CD4+T cell count,married and double-positive families,high education level,no missed medication,family support rather than discrimination,and good economic conditions were protective factors for the survival time of HIV/AIDS patients treated with HAART.The results of multivariate analysis showed that HIV/AIDS patients who started antiviral therapy at a young age,had a high baseline CD4+T cell count,and had good economic conditions had a relatively lower risk of death. Conclusion Age at the beginning of antiviral therapy,baseline CD4+T cell count,and economic conditions are influencing factors for the survival time of HIV/AIDS patients treated with HAART.
关键词
艾滋病病毒 /
抗病毒治疗 /
生存分析 /
影响因素
Key words
HIV /
Antiviral treatment /
Survival analysis /
Influencing factors
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 傅洁,岳清,庄鸣华,等.上海市 2005—2017 年艾滋病抗病毒治疗患者生存情况分析[J].实用预防医学,2020,27(11):1345-1348.
[2] Lundgren JD,Babiker AG,Gordin F,et al.Initiation of antiretroviral therapy in early asymptomatic HIV infection[J].N Engl J Med,2015,373(9):795-807.
[3] 肖明,王艳华,井文喜,等.2003—2019年山东省菏泽市HIV/AIDS患者抗病毒治疗后生存情况分析[J].预防医学论坛,2022,28(8):587-592.
[4] 中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].4版.北京:人民卫生出版社,2016.
[5] 卢珍珍,姜晨晨,倪明健,等.中国艾滋病高效抗病毒治疗研究进展[J].中国公共卫生,2020,36(4):639-642.
[6] 枞阳县人民政府. 2021年枞阳县国民经济和社会发展统计公报[R/OL].(2022-05-10)[2023-03-22].https://www.zongyang.gov.cn/sjzy/tjgb/202205/t20220510_1861198.html.
[7] 王斌,龚德光,朱洁群.鄞州区艾滋病抗病毒治疗患者生存率及影响因素分析[J].预防医学,2020,32(4):346-350.
[8] 崔倩,俞文祥,祁耀,等.盐城市2005—2015年艾滋病抗病毒治疗患者生存分析[J].实用预防医学,2018,25(5):538-542.
[9] 陈婧,徐敏,赵啸,等.北京市2005—2015年艾滋病抗病毒治疗患者生存及其影响因素[J].中华疾病控制杂志,2018,22(12):1225-1228.
[10] Sohn AH,Srikantiah P,Sungkanuparph S,et al.Transmitted HIV drug resistance in Asia[J].Curr Opin HIV AIDS,2013,8(1):27-33.
[11] 郑武,笪琴,汤恒,等.湖北省接受艾滋病抗病毒治疗的老年患者生存情况分析[J].实用预防医学,2018,25(2):176-180.
[12] 胡俊华,胡艳秋,许红霞,等.佳木斯市艾滋病抗病毒治疗患者生存率及影响因素分析[J].中国现代医生,2021,59(19):10-13.
[13] 杨中荣,李婧,董正全,等.湖州市HIV/AIDS病人ART后生存状况及相关影响因素分析[J].中国艾滋病性病,2018,24(10):997-1000.
[14] 周超,陈宗良,张维,等.重庆市艾滋病抗病毒治疗新入组病人治疗效果及其影响因素分[J].现代预防医学,2019,46(17):3091-3095.
[15] 杨小丹,田春艳,李月友,等.商洛市艾滋病抗病毒治疗病例生存率及影响因素分析[J].预防医学,2020,32(1):18-21,26.
[16] 余军,刘长,熊君,等.中老年艾滋病感染者生命质量及其影响因素研究[J].现代预防医学 ,2020,47(14):2592-2596.
[17] 薛建,程晓松,林荣,等.烟台市 HIV/AIDS 病例生命质量及影响因素分析[J].预防医学,2019,31(5):493-498.
[18] 顾思思,谢幸尔,钱湘云,等.HIV/AIDS患者抗病毒治疗决策轨迹及影响因素的质性研究[J].中国艾滋病性病,2022,28(10):1140-1144.
PDF(858 KB)
